novo semaglutide Nordisk wins EU approval for Wegovy weight-loss pill Novo Nordisk and D Young

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial

10.1007/s00401-011-0935-7 43 ChettyRVajpeyiRPenwickJL

Understanding your GLP-1 medication before you start Before you open a single package, you need to understand what you are working with

Lipolysis: Promotes fat loss by increasing metabolic rate and fatty acid oxidation

Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy

Matthias Tschp and Richard DiMarchi developed the first dual and triple agonist weight loss drugs